We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
4d Pharma Plc | LSE:DDDD | London | Ordinary Share | GB00BJL5BR07 | ORD 0.25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 16.36 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
30/12/2022 13:50 | Better than a poke in the eye with a blunt stick. Also see us rising beyond 6p when brought out of suspension | pol123 | |
30/12/2022 13:10 | Blimey. Better than nothing. | grosstonnage | |
30/12/2022 13:05 | U all have to remember... even with this huge dilution....The mkt cap will be less than 10 percent of any other company in this space ......I've a strong feeling the Vaccine data could be beneficial to our value... post admission of trading. | amaretto1 | |
30/12/2022 12:58 | I'm not interested......All iam bothered about .... this morning we had Zilch !!!Now we have a chance ...... Seres are valued at 700 million !!! | amaretto1 | |
30/12/2022 12:56 | I think he deletes them. No idea why though. You'd have to ask him | nigelpm | |
30/12/2022 12:54 | Anyone hazard a guess as to why all of Jaknife posts have been deleted ?? | dafad | |
30/12/2022 12:53 | Lots of warrants to be exercised to, but survival none the less . I think most shareholders will take that .. | mr paul b | |
30/12/2022 12:49 | 6p rescue bid. Saved but massive dilution. | neilyb675 | |
30/12/2022 12:48 | Who cares .... 1 hour ago we had nothing..... Ziltch The mkt cap is so low compared to comparable piers .....We have a chance ..... | amaretto1 | |
30/12/2022 12:48 | Yas wrong yet again. Must admit I'm surprised even though dilution will be horrendous it provides a chance. | nigelpm | |
30/12/2022 12:45 | Dilution The Ordinary Shares to be allotted pursuant to the Fundraising and the conversion of the Loan and Subordinated Loan will represent 70.65 per cent. of the Company's enlarged ordinary share capital. The Ordinary Shares to be allotted pursuant to the Fundraising, conversion of the Loan and Subordinated Loan and exercise of all Ordinary Warrants will represent 87.84 per cent. of the Company's enlarged ordinary share capital. The calculations in this section take into account interest accrued on the Loan and Subordinated Loan up to the date of this Document (where relevant) and assumes that all Pre-Payment Warrants and Ordinary Warrants are exercised in full. | qazwsxedc69 | |
30/12/2022 12:44 | Main issue ....We survive..... it only takes one lead to be successful drug wise !! | amaretto1 | |
30/12/2022 12:38 | RNS - lots to take in. rescue package etc..... The Joint Administrators are working with the Company's advisers on proposals to rescue 4D pharma, exit administration and return the Company to the control of its directors, with the intention of lifting the suspension and restoring trading in the Company's ordinary shares. | qazwsxedc69 | |
30/12/2022 12:34 | Maybe penny's ... but we survive !!!! Thankyou god. | amaretto1 | |
30/12/2022 12:33 | What a fantastic RNS for new year !!!! We survive ..... ya hoo | amaretto1 | |
30/12/2022 12:32 | Sounds promising for you guys. | guy gibson | |
20/12/2022 21:54 | Agreed yasx- it was what was signed up for (madness on the part of 4D), although have to wonder then why Oxford ever provided the loan to begin with. | podium | |
20/12/2022 15:40 | I suspect all that is happening now is the administrator bleeding out whatever cash they can still obtain for their 'services', and then the shutters will come down. A great shame as some very interesting research involved. Poor management (as ever with AIM) and a hostile loan shark lender orchestrated a take down. | podium | |
19/12/2022 17:17 | Wait for the update by 24th January. You might be pleasantly suprised. | the donald | |
19/12/2022 14:57 | Looks like it is over since if there had been any prospect of a return by now the plan would have been rolled out and Ocean would have been paid off. The reality is that currently the funding environment for nil revenue generating biotech/pharma Co's is particularly difficult, and for one in administration is is even more difficult since there are very few other options available. Peyton and Co. should have been raising as much as they possibly could when the shares hit 200p on the back of Covid fuelled sentiment in the sector in 2021 - he must surely have realised that given the high burn rate he would eventually have to tap the market again and with the shares having goner up tenfold what more was he waiting for.... Instead he took on a daft debt facility which only gave him a paltry sum and then left it until he had defaulted on the same to consider if he could raise financing by issuing equity )although he had advised the market he was confident of funds being secured, implying that there was a degree of certainty that this was likely when clearly with the benefit of hindsight it is now apparent he had not even taken any robust steps to form that view). A ten year old could have drafted a better plan that that.... | yasx |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions